IE49984B1 - Method of propagating babesia and non-babesia hemotropic parasites and method of determining the anti-babesia therapeutic effectiveness of a substance - Google Patents
Method of propagating babesia and non-babesia hemotropic parasites and method of determining the anti-babesia therapeutic effectiveness of a substanceInfo
- Publication number
- IE49984B1 IE49984B1 IE859/80A IE85980A IE49984B1 IE 49984 B1 IE49984 B1 IE 49984B1 IE 859/80 A IE859/80 A IE 859/80A IE 85980 A IE85980 A IE 85980A IE 49984 B1 IE49984 B1 IE 49984B1
- Authority
- IE
- Ireland
- Prior art keywords
- babesia
- culture medium
- parasites
- percent
- carbon dioxide
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 52
- 244000045947 parasite Species 0.000 title claims abstract description 48
- 201000008680 babesiosis Diseases 0.000 title claims abstract description 40
- 241000223836 Babesia Species 0.000 title claims abstract description 34
- 239000000126 substance Substances 0.000 title claims description 5
- 230000001225 therapeutic effect Effects 0.000 title claims description 3
- 230000001902 propagating effect Effects 0.000 title 1
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 45
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 36
- 210000004027 cell Anatomy 0.000 claims abstract description 35
- 239000001963 growth medium Substances 0.000 claims abstract description 35
- 239000000427 antigen Substances 0.000 claims abstract description 18
- 102000036639 antigens Human genes 0.000 claims abstract description 18
- 108091007433 antigens Proteins 0.000 claims abstract description 18
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 18
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 18
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 15
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 15
- 238000000338 in vitro Methods 0.000 claims abstract description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 10
- 239000001301 oxygen Substances 0.000 claims abstract description 10
- 210000002966 serum Anatomy 0.000 claims description 24
- 239000002609 medium Substances 0.000 claims description 20
- 241000283690 Bos taurus Species 0.000 claims description 19
- 241000223838 Babesia bovis Species 0.000 claims description 18
- 238000011534 incubation Methods 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 239000012888 bovine serum Substances 0.000 claims description 9
- 238000003306 harvesting Methods 0.000 claims description 7
- 230000000644 propagated effect Effects 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- 238000012423 maintenance Methods 0.000 claims description 5
- 230000003190 augmentative effect Effects 0.000 claims description 4
- 238000004320 controlled atmosphere Methods 0.000 claims 5
- 241000606646 Anaplasma Species 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical compound [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000003936 merozoite Anatomy 0.000 abstract description 23
- 230000000890 antigenic effect Effects 0.000 abstract description 4
- 230000005012 migration Effects 0.000 abstract description 4
- 238000013508 migration Methods 0.000 abstract description 4
- 230000001524 infective effect Effects 0.000 abstract description 3
- 238000002955 isolation Methods 0.000 abstract description 3
- 230000004888 barrier function Effects 0.000 abstract description 2
- 230000005540 biological transmission Effects 0.000 abstract description 2
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 238000009877 rendering Methods 0.000 abstract 1
- 244000309466 calf Species 0.000 description 14
- 208000030852 Parasitic disease Diseases 0.000 description 10
- 208000009182 Parasitemia Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000306 component Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 241000224016 Plasmodium Species 0.000 description 4
- 244000247617 Teramnus labialis var. labialis Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000606665 Anaplasma marginale Species 0.000 description 2
- 241000223848 Babesia microti Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229940124856 vaccine component Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000223840 Babesia bigemina Species 0.000 description 1
- 241000223846 Babesia canis Species 0.000 description 1
- 241001455947 Babesia divergens Species 0.000 description 1
- 241001466447 Babesia gibsoni Species 0.000 description 1
- 241000593848 Babesia major Species 0.000 description 1
- 241000223774 Babesia rodhaini Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000061220 Werneckiella equi Species 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- -1 amidinophenyl Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
- A61K39/018—Babesia antigens, e.g. Theileria antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/10—Protozoa; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/947—Microorganisms using protozoa
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3466379A | 1979-04-30 | 1979-04-30 | |
| US06/130,482 US4307191A (en) | 1979-04-30 | 1980-03-31 | Propagation of babesia parasites |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE800859L IE800859L (en) | 1980-10-30 |
| IE49984B1 true IE49984B1 (en) | 1986-01-22 |
Family
ID=26711223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE859/80A IE49984B1 (en) | 1979-04-30 | 1980-04-28 | Method of propagating babesia and non-babesia hemotropic parasites and method of determining the anti-babesia therapeutic effectiveness of a substance |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4307191A (enExample) |
| EP (1) | EP0018580B1 (enExample) |
| AU (1) | AU530639B2 (enExample) |
| CA (1) | CA1134766A (enExample) |
| DE (1) | DE3060993D1 (enExample) |
| EG (1) | EG15360A (enExample) |
| ES (1) | ES491002A0 (enExample) |
| GR (1) | GR68105B (enExample) |
| IE (1) | IE49984B1 (enExample) |
| IL (1) | IL59840A (enExample) |
| MX (1) | MX7021E (enExample) |
| PT (1) | PT71170A (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU558071B2 (en) * | 1982-11-03 | 1987-01-15 | Curators Of The University Of Missouri, The | Live vaccine for bovine babesiosis and method of preparation |
| AU578465B2 (en) * | 1984-05-09 | 1988-10-27 | Commonwealth Scientific And Industrial Research Organisation | Babesial vaccine |
| FR2589063B1 (fr) * | 1985-10-24 | 1988-08-26 | Rhone Merieux | Procede de culture de babesia canis, application a la preparation d'antigenes et de vaccins, et antigenes et vaccins contre la piroplasmose |
| GB8630851D0 (en) * | 1986-12-24 | 1987-02-04 | Department Of Agriculture For | Babesia divergens antigen & vaccine |
| AU640398B2 (en) * | 1989-08-23 | 1993-08-26 | Commonwealth Scientific And Industrial Research Organisation | Antigens and polypeptides derived from babesia (12d3 antigen) |
| US5869335A (en) * | 1995-08-25 | 1999-02-09 | Regents Of The University Of Minnesota | Method of growing rickettsiae in Ixodes scapularis tick cell culture and preparing antigens and vaccines of rickettsiae |
| US10888071B2 (en) * | 2016-02-23 | 2021-01-12 | The United States Of America, As Represented By The Secretary Of Agriculture | In vitro parasite feeding system |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3743579A (en) * | 1970-10-26 | 1973-07-03 | G Zilberblat | Method of cultivating leishmania |
-
1980
- 1980-03-31 US US06/130,482 patent/US4307191A/en not_active Expired - Lifetime
- 1980-04-15 IL IL59840A patent/IL59840A/xx unknown
- 1980-04-23 DE DE8080102168T patent/DE3060993D1/de not_active Expired
- 1980-04-23 EP EP80102168A patent/EP0018580B1/en not_active Expired
- 1980-04-24 AU AU57763/80A patent/AU530639B2/en not_active Ceased
- 1980-04-28 CA CA000350780A patent/CA1134766A/en not_active Expired
- 1980-04-28 IE IE859/80A patent/IE49984B1/en unknown
- 1980-04-28 GR GR61795A patent/GR68105B/el unknown
- 1980-04-28 MX MX808785U patent/MX7021E/es unknown
- 1980-04-29 EG EG80263A patent/EG15360A/xx active
- 1980-04-29 ES ES491002A patent/ES491002A0/es active Granted
- 1980-04-30 PT PT71170A patent/PT71170A/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL59840A0 (en) | 1980-06-30 |
| IL59840A (en) | 1983-10-31 |
| EP0018580A3 (en) | 1981-04-01 |
| ES8103161A1 (es) | 1981-02-16 |
| AU5776380A (en) | 1980-11-06 |
| MX7021E (es) | 1987-02-18 |
| EG15360A (en) | 1986-06-30 |
| GR68105B (enExample) | 1981-10-30 |
| DE3060993D1 (en) | 1982-12-02 |
| EP0018580B1 (en) | 1982-10-27 |
| AU530639B2 (en) | 1983-07-21 |
| PT71170A (en) | 1980-05-01 |
| EP0018580A2 (en) | 1980-11-12 |
| ES491002A0 (es) | 1981-02-16 |
| CA1134766A (en) | 1982-11-02 |
| IE800859L (en) | 1980-10-30 |
| US4307191A (en) | 1981-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Timms et al. | Babesia bovis: comparison of culture‐derived parasites, non‐living antigen and conventional vaccine in the protection of cattle against heterologous challenge | |
| Gradoni et al. | Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals | |
| Lillehoj | Immune response during coccidiosis in SC and FP chickens. I. Invitro assessment of T cell proliferation response to stage-specific parasite antigens | |
| Humphres et al. | Role of antibody in Coxiella burnetii infection | |
| Sattabongkot et al. | Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates | |
| US4596707A (en) | Babesia parasite antigen useful in vaccine and diagnostic reagent | |
| Ismael et al. | Mic1-3 knockout of Toxoplasma gondii is a successful vaccine against chronic and congenital toxoplasmosis in mice | |
| EP0594743A1 (en) | Continuous cell line and vaccine against avian coccidia | |
| US4307191A (en) | Propagation of babesia parasites | |
| Collins et al. | Testing the efficacy of a recombinant merozoite surface protein (MSP-1 (19) of Plasmodium vivax in Saimiri boliviensis monkeys. | |
| Rurangirwa et al. | Suppression of antibody response to Leptospira biflexa and Brucella abortus and recovery from immunosuppression after Berenil treatment | |
| Jackson et al. | Babesia bovis: culture of laboratory-adapted parasite lines and clinical isolates in a chemically defined medium | |
| Levy et al. | Cultivation and in vitro studies of Babesia | |
| Fish et al. | Vaccination of cattle against B. bovis infection with live attenuated parasites and non-viable immunogens | |
| Collins et al. | Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees | |
| TWI228419B (en) | Neospora vaccine | |
| EP0700991A1 (en) | Commercial scale concentrated preharvest tissue culture produced live T. Gondii bradyzoite and products and processes | |
| KR20010024245A (ko) | 네오스포라 백신 | |
| Grootenhuis et al. | Experimental induction of Theileria parva lawrencei carrier state in an African buffalo (Syncerus caffer) | |
| Omata et al. | Toxoplasma gondii: experimental infection in cats vaccinated with 60Co-irradiated tachyzoites | |
| Kierszenbaum et al. | Inhibition of Trypanosoma cruzi-specific immune responses by a protein produced by T. cruzi in the course of Chagas' disease | |
| Basombrío et al. | Relationship between long-term resistance to Trypanosoma cruzi and latent infection, examined by antibody production and polymerase chain reaction in mice | |
| Desowitz | Some factors influencing the induction, maintenance and degree of maternally transmitted protective immunity to malaria (Plasmodium berghei) | |
| Byrom et al. | A polarized Th1 type immune response to Cowdria ruminantium infection is detected in immune DBA/2 mice | |
| Cabrera et al. | Long-term studies on rhesus monkeys (Macaca mulatta) immunized against Plasmodium knowlesi |